S&P 500   4,320.06 (-0.23%)
DOW   33,963.84 (-0.31%)
QQQ   357.91 (+0.01%)
AAPL   174.79 (+0.49%)
MSFT   317.01 (-0.79%)
META   299.08 (+1.13%)
GOOGL   130.25 (-0.15%)
AMZN   129.12 (-0.16%)
TSLA   244.88 (-4.23%)
NVDA   416.10 (+1.45%)
NIO   8.54 (+1.07%)
BABA   88.30 (+4.98%)
AMD   96.20 (+0.09%)
T   15.13 (-1.18%)
F   12.43 (+1.89%)
MU   68.88 (+1.44%)
CGC   0.84 (+9.09%)
GE   111.25 (-1.54%)
DIS   81.25 (-1.79%)
AMC   7.63 (-0.91%)
PFE   32.69 (-0.49%)
PYPL   57.88 (-1.26%)
NFLX   379.81 (-1.13%)
S&P 500   4,320.06 (-0.23%)
DOW   33,963.84 (-0.31%)
QQQ   357.91 (+0.01%)
AAPL   174.79 (+0.49%)
MSFT   317.01 (-0.79%)
META   299.08 (+1.13%)
GOOGL   130.25 (-0.15%)
AMZN   129.12 (-0.16%)
TSLA   244.88 (-4.23%)
NVDA   416.10 (+1.45%)
NIO   8.54 (+1.07%)
BABA   88.30 (+4.98%)
AMD   96.20 (+0.09%)
T   15.13 (-1.18%)
F   12.43 (+1.89%)
MU   68.88 (+1.44%)
CGC   0.84 (+9.09%)
GE   111.25 (-1.54%)
DIS   81.25 (-1.79%)
AMC   7.63 (-0.91%)
PFE   32.69 (-0.49%)
PYPL   57.88 (-1.26%)
NFLX   379.81 (-1.13%)
S&P 500   4,320.06 (-0.23%)
DOW   33,963.84 (-0.31%)
QQQ   357.91 (+0.01%)
AAPL   174.79 (+0.49%)
MSFT   317.01 (-0.79%)
META   299.08 (+1.13%)
GOOGL   130.25 (-0.15%)
AMZN   129.12 (-0.16%)
TSLA   244.88 (-4.23%)
NVDA   416.10 (+1.45%)
NIO   8.54 (+1.07%)
BABA   88.30 (+4.98%)
AMD   96.20 (+0.09%)
T   15.13 (-1.18%)
F   12.43 (+1.89%)
MU   68.88 (+1.44%)
CGC   0.84 (+9.09%)
GE   111.25 (-1.54%)
DIS   81.25 (-1.79%)
AMC   7.63 (-0.91%)
PFE   32.69 (-0.49%)
PYPL   57.88 (-1.26%)
NFLX   379.81 (-1.13%)
S&P 500   4,320.06 (-0.23%)
DOW   33,963.84 (-0.31%)
QQQ   357.91 (+0.01%)
AAPL   174.79 (+0.49%)
MSFT   317.01 (-0.79%)
META   299.08 (+1.13%)
GOOGL   130.25 (-0.15%)
AMZN   129.12 (-0.16%)
TSLA   244.88 (-4.23%)
NVDA   416.10 (+1.45%)
NIO   8.54 (+1.07%)
BABA   88.30 (+4.98%)
AMD   96.20 (+0.09%)
T   15.13 (-1.18%)
F   12.43 (+1.89%)
MU   68.88 (+1.44%)
CGC   0.84 (+9.09%)
GE   111.25 (-1.54%)
DIS   81.25 (-1.79%)
AMC   7.63 (-0.91%)
PFE   32.69 (-0.49%)
PYPL   57.88 (-1.26%)
NFLX   379.81 (-1.13%)

Insmed (INSM) Stock Forecast, Price & News

$26.17
-0.17 (-0.65%)
(As of 09/22/2023 ET)
Compare
Today's Range
$25.75
$26.52
50-Day Range
$20.22
$26.93
52-Week Range
$16.04
$27.59
Volume
841,706 shs
Average Volume
1.23 million shs
Market Capitalization
$3.76 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$43.71

Insmed MarketRank™ Forecast

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
67.0% Upside
$43.71 Price Target
Short Interest
Bearish
8.65% of Shares Sold Short
Dividend Strength
N/A
Sustainability
-1.29
Upright™ Environmental Score
News Sentiment
0.29mentions of Insmed in the last 14 days
Based on 8 Articles This Week
Insider Trading
Selling Shares
$14,933 Sold Last Quarter
Proj. Earnings Growth
Growing
From ($5.08) to ($4.42) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.23 out of 5 stars

Medical Sector

356th out of 968 stocks

Pharmaceutical Preparations Industry

148th out of 445 stocks


INSM stock logo

About Insmed (NASDAQ:INSM) Stock

Insmed Incorporated is a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases. Insmed's first commercial product is ARIKAYCE® (amikacin liposome inhalation suspension), which is approved in the United States for the treatment of Mycobacterium avium complex (MAC) lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options. MAC lung disease is a rare and often chronic infection that can cause irreversible lung damage and can be fatal. Insmed's earlier-stage clinical pipeline includes INS1007, a novel oral reversible inhibitor of dipeptidyl peptidase 1 with therapeutic potential in non-cystic fibrosis bronchiectasis and other inflammatory diseases, and INS1009, an inhaled formulation of a treprostinil prodrug that may offer a differentiated product profile for rare pulmonary disorders, including pulmonary arterial hypertension.

INSM Price History

INSM Stock News Headlines

[BREAKING] New "Living Missile" to Replace Nuclear Missiles
CBS News Reports: "It's an entirely new type of weapon." The New York Times Reports: "No existing defense can stop it." And one small company is building them for the Pentagon!
Insmed Incorporated (NASDAQ:INSM) Sees Large Growth in Short Interest
Why Shares of Insmed Are Soaring This Week
This Stock Could Go Up 66% or More.
Marc Chaikin built the system that isolated NVDA before it became the best-performing stock of 2023.  Click here to get his latest buy.  More here.
Bank of America Securities Remains a Buy on Insmed (INSM)
Where Insmed Stands With Analysts
Insmed (INSM): A Hidden Gem or Just Modestly Undervalued?
Insmed stock climbs on positive study results; hits 52-week high
See More Headlines
Receive INSM Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Insmed and its competitors with MarketBeat's FREE daily newsletter.

INSM Company Calendar

Last Earnings
8/03/2023
Today
9/22/2023
Next Earnings (Estimated)
10/26/2023
Fiscal Year End
12/31/2023

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:INSM
Employees
373
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$43.71
High Stock Price Forecast
$53.00
Low Stock Price Forecast
$28.00
Forecasted Upside/Downside
+67.0%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
13 Analysts

Profitability

Net Income
$-481,530,000.00
Net Margins
-258.22%
Pretax Margin
-257.66%

Debt

Sales & Book Value

Annual Sales
$245.36 million
Book Value
$0.65 per share

Miscellaneous

Free Float
137,617,000
Market Cap
$3.76 billion
Optionable
Optionable
Beta
1.56

Social Links

7 Stocks to Buy And Hold Forever Cover

Click the link below and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising.

Get This Free Report

Key Executives

  • Mr. William H. Lewis J.D. (Age 50)
    Pres, CEO & Chairman
  • Mr. Paolo Tombesi (Age 55)
    Chief Financial Officer
  • Ms. Christine A. Pellizzari J.D. (Age 51)
    Chief Legal Officer & Corp. Sec.
  • Mr. Roger  AdsettMr. Roger Adsett (Age 50)
    Chief Commercial Officer
  • Dr. Paul D. Streck (Age 55)
    Advisor













INSM Stock - Frequently Asked Questions

Should I buy or sell Insmed stock right now?

13 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Insmed in the last twelve months. There are currently 13 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" INSM shares.
View INSM analyst ratings
or view top-rated stocks.

What is Insmed's stock price forecast for 2023?

13 Wall Street research analysts have issued 12-month price targets for Insmed's stock. Their INSM share price forecasts range from $28.00 to $53.00. On average, they anticipate the company's stock price to reach $43.71 in the next twelve months. This suggests a possible upside of 67.0% from the stock's current price.
View analysts price targets for INSM
or view top-rated stocks among Wall Street analysts.

How have INSM shares performed in 2023?

Insmed's stock was trading at $19.98 on January 1st, 2023. Since then, INSM shares have increased by 31.0% and is now trading at $26.17.
View the best growth stocks for 2023 here
.

Are investors shorting Insmed?

Insmed saw a increase in short interest in August. As of August 31st, there was short interest totaling 12,440,000 shares, an increase of 11.9% from the August 15th total of 11,120,000 shares. Based on an average daily trading volume, of 1,230,000 shares, the days-to-cover ratio is currently 10.1 days.
View Insmed's Short Interest
.

When is Insmed's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, October 26th 2023.
View our INSM earnings forecast
.

How were Insmed's earnings last quarter?

Insmed Incorporated (NASDAQ:INSM) issued its quarterly earnings data on Thursday, August, 3rd. The biopharmaceutical company reported ($1.78) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.10) by $0.68. The biopharmaceutical company earned $77.23 million during the quarter, compared to analyst estimates of $70.23 million. Insmed had a negative trailing twelve-month return on equity of 3,789.32% and a negative net margin of 258.22%. The business's quarterly revenue was up 18.4% on a year-over-year basis. During the same quarter in the prior year, the firm earned ($0.80) EPS.

What is Will Lewis' approval rating as Insmed's CEO?

14 employees have rated Insmed Chief Executive Officer Will Lewis on Glassdoor.com. Will Lewis has an approval rating of 78% among the company's employees.

What other stocks do shareholders of Insmed own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Insmed investors own include Gilead Sciences (gild), AbbVie (ABBV), Johnson & Johnson (JNJ), NVIDIA (NVDA), Micron Technology (MU), ACADIA Pharmaceuticals (ACAD), OPKO Health (OPK), Pfizer (PFE), Alibaba Group (BABA) and Geron (GERN).

What is Insmed's stock symbol?

Insmed trades on the NASDAQ under the ticker symbol "INSM."

Who are Insmed's major shareholders?

Insmed's stock is owned by a variety of retail and institutional investors. Top institutional shareholders include William Blair Investment Management LLC (2.98%), Bellevue Group AG (2.30%), Suvretta Capital Management LLC (2.16%), Geode Capital Management LLC (1.88%), Alliancebernstein L.P. (1.76%) and Holocene Advisors LP (1.45%). Insiders that own company stock include Alfred Altomari, Christine A Pellizzari, David R Brennan, John Drayton Wise, John Soriano, Martina MD Flammer, Melvin Md Sharoky, Michael Alexander Smith, Orlov S Nicole Schaeffer, Roger Adsett, Sara Bonstein and William Lewis.
View institutional ownership trends
.

How do I buy shares of Insmed?

Shares of INSM stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Insmed's stock price today?

One share of INSM stock can currently be purchased for approximately $26.17.

How much money does Insmed make?

Insmed (NASDAQ:INSM) has a market capitalization of $3.76 billion and generates $245.36 million in revenue each year. The biopharmaceutical company earns $-481,530,000.00 in net income (profit) each year or ($5.25) on an earnings per share basis.

How many employees does Insmed have?

The company employs 373 workers across the globe.

How can I contact Insmed?

Insmed's mailing address is 700 US Highway 202/206, Bridgewater NJ, 08807. The official website for the company is www.insmed.com. The biopharmaceutical company can be reached via phone at 908-977-9900, via email at investor.relations@insmed.com, or via fax at 732-438-0381.

This page (NASDAQ:INSM) was last updated on 9/22/2023 by MarketBeat.com Staff

My Account -